Menopausal Androgen Excess-Associated Cardio-Metabolic Risk: Clues for Ovarian Leydig Cell Tumor (Case Report and Mini-Review of Literature)

The 2017 document "Menopausal Androgen Excess - Associated Cardio-Metabolic Risk: Clues for Ovarian Leydig Cell Tumour" presented a case study of a 60-year-old woman with a history of progressive virilisation, hypertension, high red blood cell count, impaired glucose tolerance, and dyslipidemia. Her testosterone levels were 20 times above normal, and a right ovarian solid nodule was discovered. After a total hysterectomy and bilateral salpingo-oophorectomy, a Leydig cell tumour was confirmed. Post-surgery, her androgen levels normalized and her anti-hypertensive medication doses were reduced. The study concluded that for postmenopausal patients with hyperandrogenism, a Leydig cell tumour should be considered. Prolonged exposure to hyperandrogenism may generate cardiovascular abnormalities and metabolic syndrome, which are expected to significantly improve after tumor excision and removal of the source of androgen hormones.